immunosuppressive plasma cells impede t-cell-dependent immunogenic chemotherapy 
cancer-associated genetic alterations induce expression tumour antigens can activate cd8+ cytotoxic t cells ctls microenvironment established tumours promotes immune tolerance poorly understood mechanisms recently developed therapeutics overcome tolerogenic mechanisms activate tumour-directed ctls effective human cancers immune mechanisms also affect treatment outcome certain chemotherapeutic drugs stimulate cancer-specific immune responses inducing immunogenic cell death effector mechanisms previous studies revealed b cells recruited chemokine cxcl13 prostate cancer tumours promote progression castrate-resistant prostate cancer producing lymphotoxin activates ikb kinase ikk alpha-bmi1 module prostate cancer stem cells castrate-resistant prostate cancer refractory therapies examined b cell involvement acquisition chemotherapy resistance focus oxaliplatin immunogenic chemotherapeutic agent effective aggressive prostate cancer show mouse b cells modulate response low-dose oxaliplatin promotes tumour-directed ctl activation inducing immunogenic cell death three different mouse prostate cancer models refractory oxaliplatin unless genetically pharmacologically depleted b cells crucial immunosuppressive b cells plasmocytes express iga interleukin il programmed death ligand pd-l1 appearance depends tgf beta receptor signalling elimination cells also infiltrate human-therapy-resistant prostate cancer allows ctl-dependent eradication oxaliplatin-treated tumours 
